In patients with RCC, preoperative elevation of sIL-2R was associated with a higher serum level of PD-L1 and increased expression of phosphorylated Akt in the primary tumor, as well as a worse response to IFN-alpha and sequential VEGF-targeting therapy. This evidence concerns the gene AKT1 and renal cell carcinoma.